Predictors of locoregional recurrence among patients with early-stage breast cancer treated with breast-conserving therapy
- 141 Downloads
Our aim was to identify predictors of locoregional recurrence (LRR) in patients with early-stage breast cancer treated with breast-conserving therapy (BCT) and long-term follow-up.
From 1970 to 1994, 1153 patients with stage I to II breast cancer underwent BCT and radiotherapy at our institution. Patients with prior breast cancer or other primary malignancies were excluded. Clinical and pathologic characteristics evaluated were age, race, tumor size, stage, pathologic tumor margins, axillary nodal involvement, estrogen and progesterone receptor status, Black's nuclear grade, type of surgery, and use of adjuvant therapy.
Of 1083 patients, 54% presented with stage I disease and 46% with stage II disease. Median age was 50 years, and median follow-up was 9 years. Axillary nodes were positive in 31% of the patients who underwent axillary dissection. LRR developed in 6%, LRR followed by systemic recurrence in 5%, and systemic recurrence alone in 13%, 76% had no evidence of recurrence at last follow-up. Age, tumor size, positive lymph nodes, and not receiving chemotherapy or hormonal therapy were independent predictors of LRR. Disease-specific survival among patients with LRR was similar to that among patients with no recurrence.
Multidisciplinary treatment strategies should be used to accomplish durable locoregional control after BCT.
Key WordsBreast neoplasms Local recurrence Predictors Breast-conserving therapy Survival
Unable to display preview. Download preview PDF.
- 2.Treatment of early-stage of breast cancer. National Institute of Health Consensus Conference.JAMA 1991;265:391–5.Google Scholar
- 4.Harris JR, Hellman S.The Results of Primary Radiation Therapy for Early Breast Cancer at the Joint Center for Radiation Therapy. Philadelphia: JB Lippincott, 1983.Google Scholar
- 12.Rayte Z, Gazet JC, Ford HT, Easton DF, Coombes RC. Comparison of conservative surgery and radiotherapy with mastectomy in the treatment of early breast cancer.Eur J Surg Oncol 1990;16: 486–92.Google Scholar
- 16.van Dongen JA, Bartelink H, Fentiman IS, et al. Randomized clinical trial to assess the value of breast-conserving therapy in stage I and II breast cancer, EORTC 10801 trial.J Natl Cancer Inst Monogr 1992;11:1508.Google Scholar
- 19.Recht A, Connolly JL, Schnitt SJ, et al. The effect of young age on tumor recurrence in the treated breast after conservative surgery and radiotherapy.Int J Radiat Oncol Biol Phys 1987;14:3–10.Google Scholar
- 25.Miller A, von Fournier D, Kaufmann M, et al. Whole breast irradiation and boost irradiation in breast conserving therapy based on morphologic findings.Breast Dis 1989;2:121–30.Google Scholar
- 29.Hunt K, Singletary SE, Smith TL, et al. Conservation surgery and radiation: the M.D. Anderson Cancer Center experience. In: Bland KI, Copeland EM, eds.The Breast: Comprehensive Management of Benign and Malignant Disease. Philadelphia: WB Saunders, 1998:1179–82.Google Scholar
- 30.Buzdar AU, Hortobagyi GN, Kau SW.Breast Cancer Adjuvant Therapy at the M.D. Anderson Cancer Center: Results of Four Prospective Studies. Philadelphia: JB Lippincott, 1993.Google Scholar
- 34.Elkhuizen PHM, van Slooten H-J, Clahsen PC, et al. High local recurrence risk after breast-conserving therapy in node-negative premenopausal breast cancer patients is greatly reduced by one course of perioperative chemotherapy: a European Organization for Research and Treatment of Cancer Breast Cancer Cooperative Group study.J Clin Oncol 2000;18:1075–60.PubMedGoogle Scholar